The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans (Q108768848)

scientific article

Language	Label	Description	Also known as
English	The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans	scientific article

Statements

instance of

scholarly article

0 references

title

The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans (English)

0 references

2

Carolyn R Bertozzi

0 references

author name string

Benjamin A H Smith

series ordinal

1

0 references

language of work or name

English

0 references

publication date

March 2021

0 references

published in

Nature Reviews Drug Discovery

0 references

volume

20

0 references

issue

3

0 references

page(s)

217-243

0 references

cites work

Rolling cell adhesion

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

ELAM-1 Mediates Cell Adhesion by Recognition of a Carbohydrate Ligand, Sialyl-Le x

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Recognition by Elam-1 of the Sialyl-Le x Determinant on Myeloid and Tumor Cells

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

rPSGL-Ig for Improvement of Early Liver Allograft Function: A Double-Blind, Placebo-Controlled, Single-Center Phase II Study†

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

On-Chip Neo-Glycopeptide Synthesis for Multivalent Glycan Presentation

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Molecular basis of human CD22 function and therapeutic targeting

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Anti-glycan antibodies as biomarkers for diagnosis and prognosis

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

The recirculation of lymphocytes from blood to lymph in the rat

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

EFFECT OF GLYCOSIDASES ON THE FATE OF TRANSFUSED LYMPHOCYTES.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group B Streptococcus

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Selectin catch-bonds mechanotransduce integrin activation and neutrophil arrest on inflamed endothelium under shear flow.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Selectins: initiators of leucocyte adhesion and signalling at the vascular wall

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M diffuse midline gliomas.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

CD24 and Siglec-10 selectively repress tissue damage-induced immune responses.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Ganglioside GM2 as a human tumor antigen (OFA-I-1)

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe(X) and PSGL-1

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

CD62/P-selectin recognition of myeloid and tumor cell sulfatides

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

CD33 Alzheimer's risk-altering polymorphism, CD33 expression, and exon 2 splicing.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Glycopeptide analogues of PSGL-1 inhibit P-selectin in vitro and in vivo

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Properties and distribution of a lectin-like hemagglutinin differentially expressed by murine stromal tissue macrophages

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

VISTA is an acidic pH-selective ligand for PSGL-1

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Decreased venous thrombosis with an oral inhibitor of P selectin

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Structure-based discovery of glycomimetic FmlH ligands as inhibitors of bacterial adhesion during urinary tract infection.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Application of homonuclear 3D NMR experiments and 1D analogs to study the conformation of sialyl Lewis(x) bound to E-selectin

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Survival advantages conferred to colon cancer cells by E-selectin-induced activation of the PI3K-NFκB survival axis downstream of Death receptor-3

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Pan-selectin antagonism improves psoriasis manifestation in mice and man.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Efomycine M: an inhibitor of selectins?

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Antibodies from Lampreys as Smart Anti-Glycan Reagents (SAGRs): Perspectives on Their Specificity, Structure, and Glyco-genomics

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Sialylation of 3-methylcholanthrene-induced fibrosarcoma determines antitumor immune responses during immunoediting

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Association of Alzheimer's disease GWAS loci with MRI markers of brain aging

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Glycoengineered Antibodies: Towards the Next-Generation of Immunotherapeutics

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Glycans in cancer and inflammation--potential for therapeutics and diagnostics

2 references

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

5 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NRD1751

Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Human Monoclonal Antibodies to Sialyl-Lewisa (CA19.9) with Potent CDC, ADCC, and Antitumor Activity

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Noncovalent cell surface engineering: incorporation of bioactive synthetic glycopolymers into cellular membranes

2 references

5 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1021/JA710644G

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Effects of CD33 Variants on Neuroimaging Biomarkers in Non-Demented Elders

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Mechanism and function of monoclonal antibodies targeting siglec-15 for therapeutic inhibition of osteoclastic bone resorption

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Investigational CD33-targeted therapeutics for acute myeloid leukemia.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Differential expression of Cosmc, T-synthase and mucins in Tn-positive colorectal cancers

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Studies on Selectin Blockers. 6. Discovery of Homologous Fucose Sugar Unit Necessary for E-Selectin Binding

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

CD22 is a negative regulator of B-cell receptor signalling

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

PILR and PILR have a siglec fold and provide the basis of binding to sialic acid

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

CD43 is a ligand for E-selectin on CLA human T cells

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Effects of anti-adhesive therapy on kidney biomarkers of ischemia reperfusion injury in human deceased donor kidney allografts.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Loss of disialyl Lewis(a), the ligand for lymphocyte inhibitory receptor sialic acid-binding immunoglobulin-like lectin-7 (Siglec-7) associated with increased sialyl Lewis(a) expression on human colon cancers.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Recent Advance in Tumor-associated Carbohydrate Antigens (TACAs)-based Antitumor Vaccines

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer's Disease

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Selectin blockade prevents antigen-induced late bronchial responses and airway hyperresponsiveness in allergic sheep

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

E-selectin receptors on human leukocytes

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Extrinsic sialylation is dynamically regulated by systemic triggers in vivo

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

A novel selectin blocker alleviates oxidative stress of lung reperfusion injury

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Precision glycocalyx editing as a strategy for cancer immunotherapy.

2 references

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

5 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1073/PNAS.1608069113

Therapeutic potential of a novel synthetic selectin blocker, OJ-R9188, in allergic dermatitis

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Siglecs and their roles in the immune system

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

An Atlas of Human Glycosylation Pathways Enables Display of the Human Glycome by Gene Engineered Cells

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Glycosylation in cancer: mechanisms and clinical implications

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Leveraging bioorthogonal click chemistry to improve 225Ac-radioimmunotherapy of pancreatic ductal adenocarcinoma

0 references

Cell-based glycan arrays for probing glycan-glycan binding protein interactions.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Identification of Siglec Ligands Using a Proximity Labeling Method.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Myelin-associated glycoprotein demonstrated immunocytochemically in myelin and myelin-forming cells of developing rat

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Development of IsoTaG, a Chemical Glycoproteomics Technique for Profiling Intact N- and O-Glycopeptides from Whole Cell Proteomes.

2 references

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

5 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1021/ACS.JPROTEOME.6B01053

Multivalent glycan arrays

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Siglec-9 Regulates an Effector Memory CD8 T-cell Subset That Congregates in the Melanoma Tumor Microenvironment

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Binding of glycosulfopeptides to P-selectin requires stereospecific contributions of individual tyrosine sulfate and sugar residues

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

CD22 blockade restores homeostatic microglial phagocytosis in ageing brains

2 references

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

5 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/S41586-019-1088-4

Anti-P-selectin monoclonal antibody attenuates reperfusion injury to the rabbit ear

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Targeted glycan degradation potentiates the anticancer immune response in vivo

2 references

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

5 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/S41589-020-0622-X

Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Bone vascular niche E-selectin induces mesenchymal-epithelial transition and Wnt activation in cancer cells to promote bone metastasis

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Expression cloning of a functional glycoprotein ligand for P-selectin

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Calcium-Dependent Heparin-Like Ligands For L-Selectin in Nonlymphoid Endothelial Cells

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Siglec-7 is an inhibitory receptor on human mast cells and basophils.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins

2 references

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

5 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1073/PNAS.1813020116

Steering Siglec-Sialic Acid Interactions on Living Cells using Bioorthogonal Chemistry.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

A novel germline variant in CSF3R reduces N-glycosylation and exerts potent oncogenic effects in leukemia

2 references

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

5 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1158/0008-5472.CAN-18-1638

Polyvalent binding to carbohydrates immobilized on an insoluble resin

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Endothelial leukocyte adhesion molecule-1 mediates antigen-induced acute airway inflammation and late-phase airway obstruction in monkeys

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Anti-carbohydrate antibodies elicited by polyvalent display on a viral scaffold

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Mechanism of Siglec-8-induced human eosinophil apoptosis: role of caspases and mitochondrial injury

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Polysialic acid blocks mononuclear phagocyte reactivity, inhibits complement activation, and protects from vascular damage in the retina

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT-ACS Trial.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Anti-Siglec-F antibody reduces allergen-induced eosinophilic inflammation and airway remodeling

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Sulphation requirement for GlyCAM-1, an endothelial ligand for L-selectin

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

A distinct glycoform of CD44 is an L-selectin ligand on human hematopoietic cells

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2 signaling

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Siglec-8 and Siglec-9 binding specificities and endogenous airway ligand distributions and properties

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Hyaluronan: A modulator of the tumor microenvironment

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

The war against influenza: discovery and development of sialidase inhibitors

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Loss of Siglec expression on T lymphocytes during human evolution

0 references

Antibodies recognising sulfated carbohydrates are prevalent in systemic sclerosis and associated with pulmonary vascular disease

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Omics: Account for the 'dark matter' of biology

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Next generation of immune checkpoint therapy in cancer: new developments and challenges.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Efficacy of the pan-selectin antagonist Bimosiamose on ozone-induced airway inflammation in healthy subjects – A double blind, randomized, placebo-controlled, cross-over clinical trial

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Click and pick: identification of sialoside analogues for siglec-based cell targeting

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Inhaled pan-selectin antagonist Bimosiamose attenuates airway inflammation in COPD.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Siglec-7 engagement by GBS β-protein suppresses pyroptotic cell death of natural killer cells

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Galectins at a glance

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Functional role of P-selectin glycoprotein ligand 1/P-selectin interaction in the generation of tolerogenic dendritic cells

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

YSPSL (rPSGL-Ig) for improvement of early renal allograft function: a double-blind, placebo-controlled, multi-center Phase IIa study

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Structural basis for simultaneous recognition of an O-glycan and its attached peptide of mucin family by immune receptor PILR

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Alleviation of neurotoxicity by microglial human Siglec-11.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Optimal Dissociation Methods Differ for N- and O-glycopeptides

2 references

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

5 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1021/ACS.JPROTEOME.0C00218

Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Mining the O-glycoproteome using zinc-finger nuclease-glycoengineered SimpleCell lines

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion

2 references

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

5 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NCHEMBIO.1388

Fulfilling Koch's postulates in glycoscience: HCELL, GPS and translational glycobiology

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Tumor-cell killing by MAbs against fucosyl GM1, a ganglioside antigen associated with small-cell lung carcinoma

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

A versatile soluble siglec scaffold for sensitive and quantitative detection of glycan ligands

0 references

Siglec-G represses DAMP-mediated effects on T cells.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Host and pathogen hyaluronan signal through human siglec-9 to suppress neutrophil activation

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Novel Synthetic Inhibitors of Selectin-Mediated Cell Adhesion: Synthesis of 1,6-Bis[3-(3-carboxymethylphenyl)-4-(2-α-d-mannopyranosyloxy)phenyl]hexane (TBC1269)

0 references

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Antigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin/CD169

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Epitope mapping of sialyl Lewis(x) bound to E-selectin using saturation transfer difference NMR experiments.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Anti-inflammatory activity of low molecular weight polysialic acid on human macrophages

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Globo-H ceramide shed from cancer cells triggers translin-associated factor X-dependent angiogenesis

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Siglec-mediated regulation of immune cell function in disease.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic acid (PSI-697): identification of a clinical candidate from the quinoline salicylic acid series of P-selectin antagonists

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Biological roles of glycans

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

In vivo targeting of B-cell lymphoma with glycan ligands of CD22.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Sialyl Lewisx-containing oligosaccharide attenuates myocardial reperfusion injury in cats

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Distribution of CA 19-9 in adenocarcinomas and transitional cell carcinomas. An immunohistochemical study of 527 cases

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Density variant glycan microarray for evaluating cross-linking of mucin-like glycoconjugates by lectins

2 references

5 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1021/JA302193U

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis

0 references

A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent and Antitumor Activity in Preclinical Models of Small Cell Lung Cancer

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Siglec-E is a negative regulator of acute pulmonary neutrophil inflammation and suppresses CD11b β2-integrin-dependent signaling

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation.

0 references

Colonic epithelial cells express specific ligands for mucosal macrophage immunosuppressive receptors siglec-7 and -9.

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Perspectives on the significance of altered glycosylation of glycoproteins in cancer

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Distinct human α(1,3)-fucosyltransferases drive Lewis-X/sialyl Lewis-X assembly in human cells

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Dual actions of group B Streptococcus capsular sialic acid provide resistance to platelet-mediated antimicrobial killing

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Rational design and synthesis of small molecule, non-oligosaccharide selectin inhibitors: (alpha-D-mannopyranosyloxy)biphenyl-substituted carboxylic acids

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

An alteration in tumor histocompatibility induced by neuraminidase

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Identification of lipophilic ligands of Siglec5 and -14 that modulate innate immune responses

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

CD22 x Siglec-G double-deficient mice have massively increased B1 cell numbers and develop systemic autoimmunity

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Whole-Cell Cancer Vaccines Induce Large Antibody Responses to Carbohydrates and Glycoproteins

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Targeting the PSGL-1 pathway for immune modulation

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Colon carcinogenesis in inflammatory bowel disease: applying molecular genetics to clinical practice

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

P-selectin is a nanotherapeutic delivery target in the tumor microenvironment.

0 references

From carbohydrate leads to glycomimetic drugs

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

Leu-8/TQ1 is the human equivalent of the Mel-14 lymph node homing receptor

0 references

Lymphocyte homing into lymph nodes: in vitro demonstration of the selective affinity of recirculating lymphocytes for high-endothelial venules

1 reference

stated in

COCI

reference URL

https://opencitations.net/index/coci/api/v1/references/10.1038/S41573-020-00093-1

retrieved

8 October 2022

Identifiers

DOI

10.1038/S41573-020-00093-1

0 references

PMC publication ID

7812346

0 references

PubMed publication ID

33462432

0 references

The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans (Q108768848)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans (Q108768848)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Search